LTR Pharma Limited (AU:LTP) has released an update.
LTR Pharma Limited (ASX: LTP), a company dedicated to improving men’s health with an innovative erectile dysfunction nasal spray, has requested a voluntary suspension of its shares on the ASX. The suspension is in place pending an announcement of results from a significant clinical study, expected before market open on June 7, 2024. Investors are keenly awaiting the results, which could potentially impact the company’s share price and position in the market for men’s health treatments.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.
